Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 28, 2018Journal of Clinical OncologyOpen Access

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

View Full Paper
Ask AI
Bookmark
Share

Authors

TMTara C. MitchellHospital of the University of PennsylvaniaOHOmid HamidUniversité Paris-SudDSDavid C. SmithUniversity of Michigan

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mitchell et al. (2018) studied this question.

synapsesocial.com/papers/6a9f63b1d71237f70db20cf4https://doi.org/10.1200/jco.2018.78.9602
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Up-Regulation of PD-L1, IDO, and T <sub>regs</sub> in the Melanoma Tumor Microenvironment Is Driven by CD8 <sup>+</sup> T Cells2013 · 1,703 citations
  2. 2Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment2014 · 565 citations
  3. 3Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review2017 · 15,268 citations
  4. 4Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors2010 · 245 citations
  5. 5Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer2006 · 254 citations